Rapid review showed that real-world results on how nirsevimab prevented respiratory syncytial virus hospitalisations were similar to randomised trials

Acta Paediatr. 2024 Aug;113(8):1940-1941. doi: 10.1111/apa.17301. Epub 2024 May 23.

Authors

Ilari Kuitunen^{1

2}, Marjo Renko^{1

2}

Affiliations

¹ Kuopio Pediatric Research Unit, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
² Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.

PMID: 38780142
DOI: 10.1111/apa.17301

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antiviral Agents / therapeutic use
Hospitalization* / statistics & numerical data
Humans
Infant
Randomized Controlled Trials as Topic*
Respiratory Syncytial Virus Infections* / prevention & control

Substances

Antiviral Agents
Antibodies, Monoclonal, Humanized

Grants and funding